Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study

[1] Yakes FM(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2298-2308

[2] Chen J(2012)Targeting MET in cancer: rationale and progress Nat Rev Cancer 12 89-103

[3] Tan J(2013)Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer Cancer 119 7-15

[4] Yamaguchi K(2004)The hepatocyte growth factor regulatory factors in human breast cancer Clin Cancer Res 10 202-211

[5] Shi Y(2013)High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer Br J Cancer 108 1100-1105

[6] Yu P(2005)C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu Int J Cancer 113 678-682

[7] Qian F(1998)Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer Clin Cancer Res 4 659-664

[8] Chu F(2011)Molecular mechanisms and clinical applications of angiogenesis Nature 473 298-307

[9] Bentzien F(2004)Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis Cancer Res 64 2941-2955

[10] Cancilla B(2004)Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 1706-1716

[1] Yakes FM(2011)Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2298-2308

[2] Chen J(2012)Targeting MET in cancer: rationale and progress Nat Rev Cancer 12 89-103

[3] Tan J(2013)Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer Cancer 119 7-15

[4] Yamaguchi K(2004)The hepatocyte growth factor regulatory factors in human breast cancer Clin Cancer Res 10 202-211

[5] Shi Y(2013)High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer Br J Cancer 108 1100-1105

[6] Yu P(2005)C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu Int J Cancer 113 678-682

[7] Qian F(1998)Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer Clin Cancer Res 4 659-664

[8] Chu F(2011)Molecular mechanisms and clinical applications of angiogenesis Nature 473 298-307

[9] Bentzien F(2004)Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis Cancer Res 64 2941-2955

[10] Cancilla B(2004)Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients Clin Cancer Res 10 1706-1716